Varian Medical Systems Inc

Varian Medical Systems — Q2 2019 Earnings Presentation

33 slides from Varian Medical Systems's earnings presentation, Apr 24, 2019

  1. Slide 1: Second Quarter Fiscal Year 2019

    J. Michael Bruff Senior Vice President, Investor Relations [email protected] April 24, 2019 Second Quarter Fiscal Year 2019

  2. Slide 2: Forward-Looking Statements

    This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward - Looking Statements Except for historical information, this presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 199

  3. Slide 3: Q2 FY 2019 earnings Agenda

    VARIAN CONFIDENTIAL/ PROPRIETARY: DISCLOSED SOLELY FOR IMMEDIATE RECIPIENT ONLY 1. Second Quarter Results 2. Total Company Performance 3. Segment Performance 4. FY 2019 Guidance 5. Appendix Q2 FY 2019 earnings Agenda

  4. Slide 4: Q2 FY 2019 key financial metrics

    Q2 FY 2019 key financial metrics $M Q2 Y/Y Oncology Orders $766 15% Revenues $779 7% Oncology $747 7% Proton Solutions $33 2% GAAP Operating Earnings $110 1% % of Revenues 14.1% (90 bps) Non - GAAP Operating Earnings $119 (6%) % of Revenues 15.3% (220 bps) GAAP EPS $0.96 22% Non - GAAP EPS $1.05 (9%

  5. Slide 5: Long-term growth and value creation strategy

    Long - term growth and value creation strategy Global Leader in Radiation Therapy Radiation oncology OIS Radiosurgery Brachytherapy Radiation oncology treatment planning Proton therapy Radiation therapy Global Leader in Multi - Disciplinary, Integrated Cancer Care Solutions Interventional oncology S

  6. Slide 6: How we plan to achieve our strategy

    How we plan to achieve our strategy 6 Strengthen Leadership in Radiation Therapy Extend Global Footprint Expand Addressable Market Growth Priorities High Quality Care Through Innovation Build Software Services & Big Data Expertise Operational Efficiency Optimize Cash Conversion & Capital Structure S

  7. Slide 7: Executing on long-term growth strategy

    Executing on long - term growth strategy Strengthen Leadership in Radiation Therapy Extend Global Footprint Expand Addressable Market 7 KEY METRICS • Global market leader with >50% share in radiation therapy; growing share in a +10% growth market 1 • +15% Oncology orders growth in the quarter; TTM g

  8. Slide 8: Key wins

    VARIAN CONFIDENTIAL – INTERNAL USE ONLY Key wins Americas EMEA APAC Alliance Oncology - Huntsville 3 TrueBeams, 3 Halcyons, and 1 Edge system with Enterprise Software Solution HCA 4 TrueBeams and 1 Halcyon system ABC Hospital TrueBeam package Brazil Replacement of cobalt system with Halcyon Scripps

  9. Slide 9: Varian linac net installed base

    Varian linac net installed base Installed base growth Varian strengthened its global leadership in radiation therapy • Net installed base grew +4% or 338 units, driving future recurring software and services revenues • All three geographies grew respective installed base in the second quarter Q2 FY1

  10. Slide 10: Total Company Performance

    Total Company Performance varian

  11. Slide 11: Total company results (GAAP)

    Total company results (GAAP) Key P&L financial metrics 11 Note: Unless noted otherwise, all ‘Orders’ reflect Gross Orders, all growth rates are in dollars and year on year, and basis poi nts (bps) are rounded to the nearest tens. (1) TTM EPS is defined as the sum of last four quarters’ reported EPS

  12. Slide 12: Total company results (non-GAAP)

    Total company results (non - GAAP) Key P&L financial metrics 12 • Gross Orders driven by strong Oncology orders: +15% in the quarter and +13% over the trailing twelve months • Revenues growth driven by integrated platform of best - in - class hardware, software, and services • Gross Margin rate down

  13. Slide 13: Total company results: key balance sheet and cash flow metrics

    $- $100 $200 $300 Q2 FY18 Q3 FY18 Q4 FY18 Q1 FY19 Q2 FY19 - 100% Y/Y Cash Flow from Operations ($M) -$50 $0 $50 $100 $150 $200 Q2 FY18 Q3 FY18 Q4 FY18 Q1 FY19 Q2 FY19 Total Debt ($M) Total company results Key balance sheet and cash flow metrics Cash & Cash Equivalents ($M) $400 $500 $600 $700 $800 Q

  14. Slide 14: Capital allocation priorities

    • Used $51M to repurchase 420K shares in Q2 • As of the end of the quarter, 2.9M shares remaining under our existing repurchase authorization Organic R&D and Capital Investments • Investments in adaptive radiotherapy, preclinical research with the FlashFoward Consortium, and other programs • Softwar

  15. Slide 15: Segment Performance

    Segment Performance varian

  16. Slide 16: Oncology Systems segment (GAAP)

    Oncology Systems segment (GAAP) Key financial metrics 16 Note: Unless noted otherwise, all ‘Orders’ reflect Gross Orders and all growth rates are in dollars and year on year. (1) Operating earnings includes an allocation of corporate costs based on relative revenues between the operating segments. T

  17. Slide 17: Oncology Systems gross orders by geography

    17 Oncology Systems gross orders by geography AMERICAS 7% Q2 Y/Y 1 (+8% c c) 8% TTM Y/Y 1 (+8% cc) APAC 35% Q2 Y/Y (+38% cc ) 20% TTM Y/Y (+21% cc ) EMEA 17% Q2 Y/Y (+25% cc ) 18% TTM Y/Y (+19% cc ) (1) In North America, Q2 orders growth of +12% and TTM orders growth of +9%

  18. Slide 18: Proton Solutions segment (GAAP)

    Proton Solutions segment (GAAP) Key financial metrics 18 Note: Unless noted otherwise, all ‘Orders’ reflect Gross Orders and all growth rates are in dollars and year on year. NM: Not meaningful. (1) Operating earnings includes an allocation of corporate costs based on relative revenues between the o

  19. Slide 19: ProBeam proton therapy system sites

    ProBeam proton therapy system sites Operational Centers Centers Under Development Total Rooms ProBeam Sites Operational R ooms 1 Operational Sites 70 30 10 23 (1) Number of Operational Rooms may not sum up to the total number on the map due to some sites having rooms which are under development. 19

  20. Slide 20: FY 2019 Guidance

    FY 2019 Guidance varian

  21. Slide 21: Updated guidance for fiscal year 2019

    Varian consolidated Updated guidance for fiscal year 2019 21 • Guidance considers projected market growth and continued momentum of Varian’s portfolio • Updated guidance considers the following impacts to operating earnings:  $5 million increase from raise in revenue guidance  $5 million benefit f

  22. Slide 22: In summary, we are...

    FOR INVESTOR USE ONLY In summary, we are… …Driving toward our vision of a world without fear of cancer Delivering on our long - term growth and value creation strategy Growing our net installed base Extending our global footprint and market - leading, best - in - class product portfolio Becoming a g

  23. Slide 23: Appendix

    Appendix

  24. Slide 24: Non-GAAP disclosure

    Non - GAAP disclosure 24 Discussion of Non - GAAP Financial Measures This presentation includes the following non - GAAP financial measures derived from our Condensed Consolidated Statements of Earnings : non - GAAP operating earnings, non - GAAP net earnings and non - GAAP net earnings per diluted

  25. Slide 25: GAAP to non-GAAP reconciliation

    GAAP to non - GAAP reconciliation 25 (1) Includes $1.5 million, $1.9 million, $1.9 million, $1.9 million and $2.9 million respectively, in cost of revenues for the pe rio ds presented. (2) Primarily includes a $22.0 million gain on the sale of our investment in Augmenix in the first quarter of fisca

  26. Slide 26: Total revenues by sales classification

    Total revenues by sales classification 26 $M 2Q FY18 3Q FY18 4Q FY18 1Q FY19 2Q FY19 Product revenues $393.8 $365.0 $445.5 $400.2 $430.5 Y/Y 8% 14% 11% 9% 9% Service revenues $336.1 $344.1 $356.1 $340.8 $348.9 Y/Y 13% 10% 11% 9% 4% Total revenues $729.9 $709.1 $801.6 $741.0 $779.4 Y/Y 10% 12% 11% 9%

  27. Slide 27: Total revenues by product type

    Total revenues by product type 27 CC – Constant currency (1) Includes software support agreements that are recorded in revenues from service, and software licenses that are recorded in r eve nues from product, in the Condensed Consolidated Statements of Earnings. $M 2Q FY18 3Q FY18 4Q FY18 1Q FY19 2

  28. Slide 28: Total revenues by region

    Total revenues by region 28 CC – Constant currency $M 2Q FY18 3Q FY18 4Q FY18 1Q FY19 2Q FY19 Americas revenues $340.2 $342.6 $397.4 $350.4 $371.3 Y/Y 0% 2% 8% - 2% 9% Y/Y – CC - 1% 2% 8% - 2% 10% EMEA revenues $253.8 $229.7 $266.3 $251.0 $261.5 Y/Y 37% 35% 21% 30% 3% Y/Y – CC 23% 28% 22% 33% 10% AP

  29. Slide 29: Total Oncology Systems revenues by sales classification

    Total Oncology Systems revenues by sales classification 29 CC – Constant currency $M 2Q FY18 3Q FY18 4Q FY18 1Q FY19 2Q FY19 Product revenues $363.7 $326.9 $402.1 $366.6 $402.6 Y/Y 9% 29% 15% 8% 11% Y/Y – CC 7% 26% 15% 9% 14% Service revenues $334.3 $340.3 $353.5 $335.9 $344.2 Y/Y 13% 10% 11% 8% 3%

  30. Slide 30: Total Oncology Systems revenues by region

    Total Oncology Systems revenues by region 30 CC – Constant currency $M 2Q FY18 3Q FY18 4Q FY18 1Q FY19 2Q FY19 Americas revenues $321.2 $323.2 $369.5 $330.8 $357.1 Y/Y - 3% 13% 6% - 2% 11% Y/Y – CC - 3% 13% 7% - 2% 12% EMEA revenues $241.2 $208.5 $250.0 $234.5 $245.3 Y/Y 44% 32% 27% 28% 2% Y/Y – CC

  31. Slide 31: Total Proton Solutions revenues by sales classification

    Total Proton Solutions revenues by sales classification 31 $M 2Q FY18 3Q FY18 4Q FY18 1Q FY19 2Q FY19 Product revenues $30.1 $38.1 $43.4 $33.6 $27.9 Y/Y 0% - 43% - 12% 23% - 7% Service revenues $1.8 $3.8 $2.6 $4.9 $4.7 Y/Y 61% 95% - 23% 172% 151% Total revenues $31.9 $41.9 $46.0 $38.5 $32.6 Y/Y 2% -

  32. Slide 32: Oncology Systems gross orders by region

    Oncology Systems gross orders by region 32 CC – Constant currency $M 2Q FY18 3Q FY18 4Q FY18 1Q FY19 2Q FY19 Americas orders $341.4 $362.9 $505.7 $335.9 $366.1 Y/Y 2% 9% 6% 12% 7% Y/Y – CC 2% 9% 6% 12% 8% EMEA orders $199.3 $259.1 $360.8 $218.3 $233.3 Y/Y 11% 27% 14% 15% 17% Y/Y – CC 0% 21% 15% 17%

  33. Slide 33: Our promise: People powering victories

    Our promise 33 People powering victories Imagine a world without fear of cancer. We do, every day. We innovate new technologies for treating cancer and for connecting clinical teams to advance patient outcomes. Through ingenuity we inspire new victories and empower people in the fight against cancer

Varian Medical Systems — Q2 2019 Earnings Presentation on 6ix